TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›RXO›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

RXO, Inc. (RXO) financials

Income statement

RXO, Inc. (RXO) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Revenue$3.36B$4.69B$4.80B$3.93B$4.55B$5.74B
Revenue growth—39.7%2.3%-18.1%15.9%26.2%
Operating income$60.0M$192M$123M$39.0M-$56.0M-$79.0M
Operating margin1.8%4.1%2.6%1.0%-1.2%-1.4%
Net income$43.0M$150M$92.0M$4.00M-$290M-$100M
Net margin1.3%3.2%1.9%0.1%-6.4%-1.7%
EPS (diluted)$0.37$1.30$0.79$0.03-$2.17-$0.59

Cash flow

RXO, Inc. (RXO) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$25.0M$155M$310M$89.0M-$12.0M$51.0M
Capital expenditures$47.0M$39.0M$57.0M$64.0M$45.0M$59.0M
Free cash flow-$22.0M$116M$253M$25.0M-$57.0M-$8.00M
Share buybacks—$0.00$0.00$2.00M$0.00$0.00

Balance sheet

RXO, Inc. (RXO) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$70.0M$29.0M$98.0M$5.00M$35.0M$17.0M
Total assets—$2.07B$2.03B$1.82B$3.41B$3.28B
Shareholders' equity$1.07B$1.07B$587M$594M$1.61B$1.54B
Retained earnings—$0.00$2.00M$6.00M-$284M-$384M
Shares (wtd avg diluted)115M115M116M119M133M168M

Every figure is extracted from RXO, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is RXO, Inc.'s annual revenue?
RXO, Inc. (RXO) reported $5.74B of revenue for fiscal year 2025 — up 26.2% from $4.55B in FY2024, per its annual report filed with the SEC.
Is RXO, Inc. profitable?
Not in FY2025 — RXO reported a net loss of $100M, per SEC filings.
What is RXO, Inc.'s free cash flow?
-$8.00M in FY2025 (operating cash flow $51.0M minus $59.0M of capital expenditures), from the SEC cash-flow statement.
Does RXO pay a dividend?
RXO, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full RXO analysis — verdict, score & filings →Is RXO a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.